Table 1 Therapy courses according to AIEOP LNH-97 protocol plus rituximab. According to the treatment risk group (R3), patients received the following chemotherapy cycles: prephase, AA, BB, CC, AA, BB

_Prephase

_{Dexamethasone orally/IV} ^a

_mg/sqm

₅

₅

₁₀

₁₀

₁₀

_{Cyclophosphamide IV (1 h)}

_{200 mg/sqm/day}

_x

_x

_{MTX+ARA-C+PDN IT}

_{12 mg +30mg+10mg} ^b

_x

_{Cycle AA}

_{Rituximab IV}

_{375 mg/sqm}

_x ^f

_{Dexamethasone orally/IV} ^a

_{10 mg/sqm}

_x

_x

_x

_x

_x

_{Vincristine IV} ^c

_{1.5 mg/sqm}

_x

_{Methotrexate IV} ^d

_{5 g/sqm}

_x

_{Ifosfamide IV (1 h)}

_{800 mg/sqm}

_x

_x

_x

_x

_x

_{Etoposide IV (2 h)}

_{100 mg/sqm}

_x

_x

_{Cytarabine IV (1 h)}

_{150 mg/sqm}

_{x -x} ^e

_{x - x} ^e

_{MTX+ARA-C+PDN IT}

_{12 mg +30mg+10mg} ^b

_x

_{Cycle BB}

_{Rituximab IV}

_{375 mg/sqm}

_x

_{Dexamethasone orally/IV} ^a

_{10 mg/sqm}

_x

_x

_x

_x

_x

_{Vincristine IV} ^c

_{1.5 mg/sqm}

_x

_{Methotrexate IV} ^d

_{5 g/sqm}

_x

_{Cyclophosphamide IV (1 h)}

_{200 mg/sqm/day}

_x

_x

_x

_x

_x

_{Doxorubicin IV (4 h)}

_{25 mg/sqm}

_x

_x

_{MTX+ARA-C+PDN IT}

_{12 mg +30mg+10mg} ^b

_x

_{Cycle CC}

_{Rituximab IV}

_{375 mg/sqm}

_x

_{Dexamethasone orally/IV} ^a

_{20 mg/sqm}

_x

_x

_x

_x

_x

_{Vindesine IV} ^c

_{3 mg/sqm}

_x

_{Cytarabine IV (3 h)}

_{3 g/sqm}

_{x -x} ^e

_{x - x} ^e

_{Etoposide IV (2 h)}

_{100 mg/sqm}

_x

_x

_{Mtx+ARA-C+PDN IT}

_{12 mg +30mg+10mg} ^b

_x